Floatz logo

Zanubrutinib

Immunochemotherapy

Zhejiang Cancer HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Immunochemotherapy cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Zhejiang Cancer Hospital
Phase 2CCC
VINDESINE
Zhejiang Cancer Hospital
Phase 2CCC
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Zhejiang Cancer Hospital
Phase 2CCC
Obinutuzumab
Zhejiang Cancer Hospital
Phase 2CCC

Same molecule, other indications

Zanubrutinib is also rated in:

B-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
splenic marginal zone lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
marginal zone lymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →